Aldeyra Therapeutics has released positive topline results from a phase 3 clinical trial investigating reproxalap in patients with allergic conjunctivitis, according to a press release.
The INVIGORATE trial achieved statistical significance for the primary and secondary endpoints for 0.25% reproxalap ophthalmic solution. The results align with previous phase 2 and phase 3 trials for indications such as dry eye disease. Ninety-five patients with allergic conjunctivitis were enrolled in the randomized, double-masked, vehicle-controlled, two-way crossover design allergen chamber trial.
For the